Médicalisa: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Médicalisa
Largest movements
- Cash +€39,682
up €39,682 (+79.9%), from €49,664 to €89,346
mainly Net result for the year (+€37,582) and Receivables within one year (+€6,484)
- Receivables within one year -€6,484
down €6,484 (-34.9%), from €18,559 to €12,075
of which Trade receivables: -€4,843
- Receivables after one year +€4,000
new in 2025: €4,000
- Profit (loss) carried forward +€37,582
up €37,582 (+63.6%), from €59,088 to €96,671
- Tax, wage and social debts -€1,950
down €1,950 (-30.8%), from €6,328 to €4,378
of which Taxes: -€1,971
- Trade debts +€1,512
up €1,512 (+494%), from €306 to €1,819
- Gross operating margin -€27,336
down €27,336 (-36.7%), from €74,545 to €47,209
- Taxes -€5,670
down €5,670 (-36.5%), from €15,516 to €9,847
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €68,223 | €105,451 | +€37,228 | +54.6% |
| Current assets | 29/58 | €68,223 | €105,451 | +€37,228 | +54.6% |
| Amounts receivable after more than one year | 29 | - | €4,000 | +€4,000 | |
| Other amounts receivable | 291 | - | €4,000 | +€4,000 | |
| Amounts receivable within one year | 40/41 | €18,559 | €12,075 | -€6,484 | -34.9% |
| Trade receivables | 40 | €12,918 | €8,075 | -€4,843 | -37.5% |
| Other amounts receivable | 41 | €5,641 | €4,000 | -€1,641 | -29.1% |
| Cash at bank and in hand | 54/58 | €49,664 | €89,346 | +€39,682 | +79.9% |
| Deferred charges and accrued income | 490/1 | - | €30 | +€30 | |
| Total equity and liabilities | 10/49 | €68,223 | €105,451 | +€37,228 | +54.6% |
| Equity | 10/15 | €61,588 | €99,171 | +€37,582 | +61.0% |
| Contributions | 10/11 | €2,500 | €2,500 | = | 0.0% |
| Profit (loss) carried forward | 14 | €59,088 | €96,671 | +€37,582 | +63.6% |
| Amounts payable | 17/49 | €6,634 | €6,280 | -€354 | -5.3% |
| Amounts payable within one year | 42/48 | €6,634 | €6,280 | -€354 | -5.3% |
| Trade debts | 44 | €306 | €1,819 | +€1,512 | +494% |
| Suppliers | 440/4 | €306 | €1,819 | +€1,512 | +494% |
| Taxes, remuneration and social security | 45 | €6,328 | €4,378 | -€1,950 | -30.8% |
| Taxes | 450/3 | €3,798 | €1,827 | -€1,971 | -51.9% |
| Remuneration and social security | 454/9 | €2,530 | €2,551 | +€21 | +0.8% |
| Other amounts payable | 47/48 | - | €84 | +€84 | |
| Other operating charges | 640/8 | - | €121 | +€121 | |
| Gross operating margin | 9900 | €74,545 | €47,209 | -€27,336 | -36.7% |
| Operating profit (loss) | 9901 | €74,545 | €47,088 | -€27,457 | -36.8% |
| Financial income | 75/76B | €62 | €427 | +€366 | +592% |
| Recurring financial income | 75 | €62 | €427 | +€366 | +592% |
| Financial charges | 65/66B | €2 | €87 | +€85 | +3,799% |
| Recurring financial charges | 65 | €2 | €87 | +€85 | +3,799% |
| Profit (loss) for the period before taxes | 9903 | €74,605 | €47,429 | -€27,176 | -36.4% |
| Income taxes | 67/77 | €15,516 | €9,847 | -€5,670 | -36.5% |
| Profit (loss) for the period | 9904 | €59,088 | €37,582 | -€21,506 | -36.4% |
| Profit (loss) for the period to be appropriated | 9905 | €59,088 | €37,582 | -€21,506 | -36.4% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 1 November 2026 via checked.be.